免疫染色用の甲状腺がん組織マーカー抗体 抗HBME-1抗体

The monoclonal antibody against HBME-1 targets an unknown antigen of mesothelial microvilli. HBME-1 is abnormally expressed in thyroid cancer, showing cytoplasmic location with membrane accentuation. Anti-HBME-1 has been most extensively investigated as an immunochemical (IHC) marker in thyroid cancer. It has a sensitivity of 78.3% and specificity of 85.4% in 10 studies using preoperative fine needle aspirate (FNA) specimens. Similar sensitivity of 77% and specificity of 83% have been reported in meta-analysis of 21 IHC studies on formalin-fixed paraffin-embedded tissue sections. Most papillary thyroid carcinomas (PTC) show diffuse positive staining for HBME-1 (55%–100%; mean, 88%). One study has reported a sensitivity of 70% and 45% for the classical and follicular variant of PTC, respectively. HBME-1 detection in thyroid follicular carcinomas in different studies has varied between 50% and 100% (mean, 75%). A small series of an oncocytic variant of papillary and follicular carcinoma have demonstrated positive HBME-1 staining in 13% to 66% of cases . Poorly differentiated and anaplastic carcinomas also often express HBME-1 (67%–91% and 0%–50%, respectively). HBME-1 is stronglyexpressed in mesothelium, bronchial epithelium, endocervical epithelium and cartilage; variably positive or focal positive in alveolar lining cells of the lung, myoepithelium of breast ducts, endometrial glands with luminal (apical) staining pattern and scattered histiocytes in lymphoid tissue. HBME-1 is negative in epithelium of GI tract, squamous epithelium, liver, kidney, testis, thyroid, placenta, connective tissue, muscle (skeletal and smooth), skin epidermis and dermis and lymphoid tissue.